Openheimer analyst Rohit Vanjani is weighing in on Opko Health Inc. (NYSE:OPK), after the company released its first-quarter results, posting revenue of $30.
In a research report released Tuesday, Oppenheimer analyst Rohit Vanjani reiterated a Perform rating on Opko Health Inc. (NYSE:OPK), as shares have traded up nearly 45% …
Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Opko Health (NYSE:OPK) with a price target of $12, which represents a potential upside …
In a research report issued today, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Opko Health (NYSE:OPK) with a $12 price target, following yesterday’s news …
